Table 2.
Haematological analysis
| Group | Haematological values |
|||||||
|---|---|---|---|---|---|---|---|---|
| Leucocytes |
Lymphocytes |
Erythrocytes |
Platelets |
|||||
| Week 0 | Week 64 | Week 0 | Week 64 | Week 0 | Week 64 | Week 0 | Week 64 | |
| HASPB1 | 14.3 ± 3.2 | 10.0 ± 4.7* | 2.10 ± 0.82 | 1.09 ± 0.45* | 7.08 ± 0.37 | 4.68 ± 1.02* | 301 ± 62 | 203 ± 94* |
| H1 | 13.7 ± 2.3 | 9.7 ± 3.8* | 1.80 ± 0.39 | 1.55 ± 0.82 | 6.35 ± 0.52 | 5.01 ± 1.01* | 295 ± 97 | 216 ± 188 |
| HASPB1 + H1 | 11.3 ± 1.9 | 6.8 ± 3.3* | 2.54 ± 0.52 | 1.19 ± 0.75* | 7.62 ± 1.88 | 4.27 ± 1.38* | 367 ± 51 | 172 ± 92* |
| Montanide | 12.0 ± 4.4 | 6.8 ± 3.2 | 2.02 ± 1.28 | 0.78 ± 0.32 | 6.63 ± 0.48 | 4.51 ± 1.88 | 274 ± 89 | 169 ± 41* |
| MML | 11.6 ± 2.6 | 5.5 ± 2.6* | 1.94 ± 0.72 | 0.78 ± 0.32* | 6.94 ± 0.17 | 3.59 ± 0.92* | 353 ± 89 | 181 ± 80* |
| MPL-SE | 10.5 ± 1.0 | 8.0 ± 4.0 | 1.57 ± 0.58 | 1.8 ± 0.43 | 7.08 ± 0.43 | 5.16 ± 1.23* | 316 ± 25 | 244 ± 162 |
| Control | 13.5 ± 2.4 | 7.2 ± 3.5* | 2.26 ± 0.69 | 0.98 ± 0.60* | 6.91 ± 0.85 | 4.21 ± 1.07* | 273 ± 66 | 171 ± 59* |
Values are shown for each group at pre-challenge (week 0) and at the end of the study (week 64).
*
Statistically significant (p < 0.05) differences between the value at pre-challenge (Week 0) and at the end of the trial (Week 64).